文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

大环内酯类治疗对因社区获得性肺炎入住ICU患者长期死亡率的影响:靶向最大似然估计与生存分析

Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.
PubMed 文献 · Crit Care · 2023-05-31
一句话结论在因社区获得性肺炎入住ICU的成人中,基于大环内酯类的治疗与6个月和12个月死亡风险降低约三成相关(HR 0.69和0.72)。

该研究基于MIMIC-IV数据库中16岁及以上因社区获得性肺炎入住ICU的3775例患者,其中1154例接受基于大环内酯类的治疗。非大环内酯组6个月死亡率31.5%(363/1154)vs 39.5%(1035/2621),12个月死亡率39.0%(450/1154)vs 45.7%(1198/2621),p均<0.001。大环内酯类治疗降低6个月死亡风险[HR 0.69(0.60, 0.78),p<0.001]和12个月死亡风险[HR 0.72(0.64, 0.81),p<0.001]。经靶向最大似然估计模拟随机对照试验后保护效应持续,加性效应估计为-0.069;排除铜绿假单胞菌或MRSA肺炎的敏感性分析后该效应仍存在。

要点

  • 在因社区获得性肺炎入住ICU的成人中,基于大环内酯类的治疗与6个月死亡风险降低相关[HR 0.69(0.60, 0.78),p<0.001]。
  • 基于大环内酯类的治疗与12个月死亡风险降低相关[HR 0.72(0.64, 0.81),p<0.001]。
  • 非大环内酯组6个月死亡率为39.5%(1035/2621),大环内酯组为31.5%(363/1154),p<0.001。
  • 非大环内酯组12个月死亡率为45.7%(1198/2621),大环内酯组为39.0%(450/1154),p<0.001。
  • 与长期死亡率相关的主要危险因素为Charlson合并症指数、SAPS II、感染性休克和呼吸衰竭。

适用人群与场景

  • MIMIC-IV数据库中登记、年龄16岁及以上、因社区获得性肺炎入住ICU的患者。
  • 敏感性分析排除铜绿假单胞菌或MRSA肺炎患者,以控制医疗保健相关肺炎(HCAP)分类的影响。

研究设计与关键结果

  • 研究类型为基于MIMIC-IV数据库的队列研究,共纳入3775例因社区获得性肺炎入住ICU的患者,其中1154例接受基于大环内酯类的治疗。
  • 采用多因素分析、靶向最大似然估计(TMLE)模拟随机对照试验及生存分析,检验基于大环内酯类治疗对入院后6个月和12个月死亡率的影响。
  • 非大环内酯组长期临床结局更差:6个月死亡率31.5%(363/1154)vs 39.5%(1035/2621),p<0.001;12个月死亡率39.0%(450/1154)vs 45.7%(1198/2621),p<0.001。
  • 与长期死亡率相关的主要危险因素为Charlson合并症指数、SAPS II、感染性休克和呼吸衰竭。
  • 基于大环内酯类的治疗降低6个月死亡风险[HR(95%CI)0.69(0.60, 0.78),p<0.001]和12个月死亡风险[0.72(0.64, 0.81),p<0.001]。
  • 经TMLE后保护效应持续,加性效应估计为-0.069。
  • 敏感性分析排除铜绿假单胞菌或MRSA肺炎患者后,该效应仍存在。

证据类型、等级与局限

  • 证据类型:基于MIMIC-IV数据库的队列研究,采用靶向最大似然估计模拟随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在因社区获得性肺炎入住ICU的成人中,基于大环内酯类的治疗与6个月和12个月死亡风险降低相关,此效应在模拟随机对照试验的TMLE分析和排除铜绿假单胞菌或MRSA肺炎的敏感性分析后仍存在。

指南或共识出处

  • 国际社区获得性肺炎指南推荐包含基于大环内酯类的治疗方案(原文未写明具体指南名称)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Patients with community-acquired pneumonia (CAP) admitted to the intensive care unit (ICU) have high mortality rates during the acute infection and up to ten years thereafter. Recommendations from international CAP guidelines include macrolide-based treatment. However, there is no data on the long-term outcomes of this recommendation. Therefore, we aimed to determine the impact of macrolide-based therapy on long-term mortality in this population.

METHODS: Registered patients in the MIMIC-IV database 16 years or older and admitted to the ICU due to CAP were included. Multivariate analysis, targeted maximum likelihood estimation (TMLE) to simulate a randomised controlled trial, and survival analyses were conducted to test the effect of macrolide-based treatment on mortality six-month (6 m) and twelve-month (12 m) after hospital admission. A sensitivity analysis was performed excluding patients with Pseudomonas aeruginosa or MRSA pneumonia to control for Healthcare-Associated Pneumonia (HCAP).

RESULTS: 3775 patients were included, and 1154 were treated with a macrolide-based treatment. The non-macrolide-based group had worse long-term clinical outcomes, represented by 6 m [31.5 (363/1154) vs 39.5 (1035/2621), p < 0.001] and 12 m mortality [39.0 (450/1154) vs 45.7 (1198/2621), p < 0.001]. The main risk factors associated with long-term mortality were Charlson comorbidity index, SAPS II, septic shock, and respiratory failure. Macrolide-based treatment reduced the risk of dying at 6 m [HR (95% CI) 0.69 (0.60, 0.78), p < 0.001] and 12 m [0.72 (0.64, 0.81), p < 0.001]. After TMLE, the protective effect continued with an additive effect estimate of - 0.069.

CONCLUSION: Macrolide-based treatment reduced the hazard risk of long-term mortality by almost one-third. This effect remains after simulating an RCT with TMLE and the sensitivity analysis for the HCAP classification.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reyes LF, Garcia E, Ibáñez-Prada ED, et al. Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis. Crit Care. 2023. PMID: 37259125. doi:10.1186/s13054-023-04466-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。